Long-term graft survival rate of zero-mismatch kidney transplants for HLA-DRB1. 1994

Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
Department of Urology and Kidney Transplant Center, Hyogo Prefectural Nishinomiya Hospital, Japan.

The study of a two-locus association between HLA-B and -DRB 1 revealed a significant 43 linkage disequilibrium. Donor-recipient HLA-DRB1 was determined by these 43 linkages. Zero-mismatch for HLA-DRB1 had a significant effect on the graft survival rate in living related and cadaver transplants. The 5-year graft survival rate was 94% in the zero-mismatch group for HLA-DRB1, 96% for related transplants, 92% for cadaver cases, and 94% in HLA identical siblings. A statistically significant difference was found between the zero-mismatch group for HLA-DRB1 and mismatch groups for HLA-DRB1 or HLA-DR (P < 0.01). The zero-mismatch group for HLA-DRB1 had mismatches for HLA-A and/or HLA-B in 46 of 70 cases (66%). No significant differences in the rejection rate was observed between zero-mismatch and mismatch cases for HLA-A and/or -B in the zero-mismatch group for HLA-DRB1. In the second step, genotyping was conducted in 118 cases. The 5-year graft survival rate was 93% in the zero-mismatch group for HLA-DRB1 and 86% in mismatch group (not a significant difference). We concluded that zero-mismatch transplant for HLA-DRB1 had a better long-term graft survival rate regardless of HLA class I.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009679 Nuclear Family A family composed of spouses and their children. Daughters,Sons,Daughter,Families, Nuclear,Family, Nuclear,Nuclear Families,Son
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015235 HLA-B Antigens Class I human histocompatibility (HLA) surface antigens encoded by more than 30 detectable alleles on locus B of the HLA complex, the most polymorphic of all the HLA specificities. Several of these antigens (e.g., HLA-B27, -B7, -B8) are strongly associated with predisposition to rheumatoid and other autoimmune disorders. Like other class I HLA determinants, they are involved in the cellular immune reactivity of cytolytic T lymphocytes. Antigens, HLA-B,HLA-B Antigen,HLA-B,Antigen, HLA-B,Antigens, HLA B,HLA B Antigen,HLA B Antigens

Related Publications

Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
December 1993, Transplantation proceedings,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
August 1994, Transplantation proceedings,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
July 1994, Transplantation,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
April 1994, Transplantation,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
September 2001, Transplantation proceedings,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
January 1984, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
January 1992, Clinical transplants,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
December 1994, Immunology and cell biology,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
November 2012, Transplantation proceedings,
Y Ichikawa, and N Fujimoto, and M Hashimoto, and M Kyo, and T Kinoshita, and S Takahara, and M Yamasaki, and S Ohshima, and H Ihara, and T Fukunishi, and M Sata, and H P Amemiya, and T Hanafusa, and S Nagano
February 1993, Transplantation proceedings,
Copied contents to your clipboard!